Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study | Synapse
September 13, 2024Open Access
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
Key Points
Key points are not available for this paper at this time.
Abstract
Merck Sharp & Dohme, National Institutes of Health, and National Cancer Institute.